Aytu Biopharma (AYTU) Debt to Equity (2017 - 2025)
Aytu Biopharma (AYTU) has disclosed Debt to Equity for 13 consecutive years, with $0.83 as the latest value for Q4 2025.
- On a quarterly basis, Debt to Equity rose 116.91% to $0.83 in Q4 2025 year-over-year; TTM through Dec 2025 was $0.83, a 116.91% increase, with the full-year FY2025 number at $0.67, up 40.41% from a year prior.
- Debt to Equity was $0.83 for Q4 2025 at Aytu Biopharma, down from $1.09 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $1.09 in Q3 2025 to a low of $0.01 in Q4 2021.
- A 5-year average of $0.44 and a median of $0.46 in 2023 define the central range for Debt to Equity.
- Peak YoY movement for Debt to Equity: crashed 88.0% in 2021, then surged 3689.35% in 2022.
- Aytu Biopharma's Debt to Equity stood at $0.01 in 2021, then soared by 3689.35% to $0.48 in 2022, then fell by 4.64% to $0.46 in 2023, then decreased by 15.8% to $0.38 in 2024, then soared by 116.91% to $0.83 in 2025.
- Per Business Quant, the three most recent readings for AYTU's Debt to Equity are $0.83 (Q4 2025), $1.09 (Q3 2025), and $0.67 (Q2 2025).